Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Total revenue $ 36,629 $ 8,486
Operating expenses:    
Research and development 19,042 21,497
General and administrative 5,802 7,620
Total operating expenses 24,844 29,117
Income/(loss) from operations 11,785 (20,631)
Interest and other income, net 455 70
Interest and other expense, net (1,395) (1,050)
Net income/(loss) $ 10,845 $ (21,611)
Net income/(loss) per share attributable to common shareholders:    
Basic $ 0.19 $ (0.38)
Diluted $ 0.19 $ (0.38)
Weighted average number of shares used in net income/(loss) per share calculations:    
Basic 56,351,647 56,305,049
Diluted 56,351,647 56,305,049
Research And Development Revenue    
Total revenue $ 33,627 $ 8,486
Grant Revenue    
Total revenue $ 3,002 $ 0